NAFLD: Rising Global Health Issue Tied to Metabolic Dysfunction, Gut Microbiome, and Emerging Therapies
Non-alcoholic fatty liver disease (NAFLD) is characterized by ≥5% hepatic steatosis unrelated to alcohol or drug use, primarily driven by metabolic dysfunction, obesity, and type 2 diabetes.
MASLD: A Growing Global Health Concern Driven by Obesity, Diabetes, and Cardiovascular Risks
The terms nonalcoholic fatty liver disease (NAFLD) and nonalcoholic steatohepatitis (NASH) have been replaced by metabolic-dysfunction-associated steatotic liver disease (MASLD) to reduce stigmatization.
Understanding MASH: The Severe Stage of MASLD Linked to Inflammation and Liver Damage
Metabolic dysfunction-associated fatty liver disease (MASLD), previously known as NAFLD or MAFLD, is a liver condition associated with metabolic syndrome and affects over 30% of the global adult population. MASLD is typically diagnosed when more than 5% of liver cells (hepatocytes) exhibit steatosis alongside metabolic conditions like obesity, type 2 diabetes, or dyslipidemia.
Patients Share Stories About Non-Alcoholic Fatty Liver Disease
Non-alcoholic fatty liver disease (NAFLD) is a liver condition unrelated to alcohol consumption but can progress to serious complications like cirrhosis or liver cancer.
Rezdiffra and Noncirrhotic Non-alcoholic Steatohepatitis
The first US Food and Drug Administration-approved medication to treat noncirrhotic non-alcoholic steatohepatitis, otherwise known as NASH, is Rezdiffra (resmetirom).
New Clinical Practice Update on Nonalcoholic Fatty Liver Disease in Lean Individuals
The American Gastroenterological Association has issued a new clinical practice update focused on the diagnosis, staging, and management of nonalcoholic fatty liver disease (NAFLD) in lean individuals.
Community Conversation on Liver Disease Highlights New Nomenclature and Its Impact on Patient Care
A community conversation hosted by the Fatty Liver Foundation focused on the significance of the new nomenclature for liver diseases.
Nonalcoholic Fatty Liver Disease: A Growing Health Concern Linked to Type 2 Diabetes
Nonalcoholic fatty liver disease (NAFLD) is a common chronic liver condition strongly linked to type 2 diabetes (T2D). In the US, it affects about 35% of the population and 52% of those with T2D.
Rising Obesity Fuels Nonalcoholic Fatty Liver Disease
The global rise in obesity has significantly increased the prevalence of non-alcoholic fatty liver disease (NAFLD), which can progress to severe conditions like nonalcoholic steatohepatitis (NASH) and hepatocellular carcinoma (HCC).
Nonalcoholic Fatty Liver Disease: The Impact of Significant Weight Loss
Non-alcoholic fatty liver disease (NAFLD) is the most prevalent liver disease globally, and endoscopic sleeve gastroplasty (ESG) has emerged as a feasible and effective intervention for managing obesity.
